Moderna settles Arbutus and Genevant patent litigation for a $950 million lump sum

Moderna agreed on March 3, 2026 to settle all worldwide patent litigation with Arbutus and Genevant over lipid nanoparticle technology, with no future royalties on its vaccines. The $950 million lump sum was due by July 8, 2026, and the company booked the charge in the first quarter. A separate $1.3 billion payment remains possible if a federal appeals court rejects Moderna's government-contractor defense.

• Settlement effective March 3, 2026, resolving all related patent litigation
• Lump-sum payment: $950 million, due on or before July 8, 2026
• No future royalties owed on covered vaccines, including mNEXSPIKE and mCOMBRIAX
• Contingent payment of up to $1.3 billion if the Section 1498 defense fails on appeal